Although long term safety and efficacy data are not yet available for these inhibitors, the short term efficacy of tofacitinib, a Jak inhibitor in RA seems to be comparable to that of anti-TNF agents while side effects, such as infection, anemia and neutropenia, appear to be directly related to its mode of action [53]. Here, TNF is linked to anemia (phenotype).